Maureen Canavan, PhD, MPH
Associate Research Scientist (General Medicine)Cards
About
Titles
Associate Research Scientist (General Medicine)
Affiliated Faculty, Yale Institute for Global Health
Biography
Maureen E. Canavan, Ph.D., is an epidemiologist at Yale Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) since 2017. In addition to working the MCBS data, she works as part of the Yale Cancer Center’s Cancer Care Innovations Lab (CaCIL) team evaluating quality metrics for cancer care. Her research interests include health management, employment, and end of life care. Prior to her work at COPPER, she was a member of the Global Health Leadership Institute (GHLI) team, she conducts qualitative and quantitative data analysis of GHLI studies in countries including Ghana, Ethiopia and China. She received an M.P.H. from the University of Medicine and Dentistry of New Jersey, School of Public Health and a B.S. from Pennsylvania State University.
Appointments
General Internal Medicine
Associate Research ScientistPrimary
Other Departments & Organizations
- COPPER Center
- General Internal Medicine
- Internal Medicine
- Obesity Research Working Group
- Yale Institute for Global Health
Education & Training
- PhD
- Yale University Graduate School (2011)
- MPH
- University of Medicine and Dentistry of New Jersey, School of Public Health, Epidemiology, Health Education, and Behavioral Science (2005)
- BS
- Pennsylvania State University, Biology (2003)
Research
Publications
2024
Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation?
Ayoade O, Canavan M, Caturegli G, Boffa D. Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation? Lung Cancer 2024, 198: 108032. PMID: 39561624, DOI: 10.1016/j.lungcan.2024.108032.Peer-Reviewed Original ResearchCost-Related Prescription Drug Rationing by Adults With Obesity
Chen A, Borden C, Canavan M, Ross J, Oladele C, Lipska K. Cost-Related Prescription Drug Rationing by Adults With Obesity. JAMA Network Open 2024, 7: e2433000. PMID: 39499520, PMCID: PMC11539006, DOI: 10.1001/jamanetworkopen.2024.33000.Peer-Reviewed Original ResearchSystemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis.
Adelson K, Canavan M, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Cheng L. Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 20: 276-276. DOI: 10.1200/op.2024.20.10_suppl.276.Peer-Reviewed Original ResearchEnd-of-lifeSystemic anticancer therapyDay of deathIntensive care unit useIntensive care unitHealthcare utilizationEmergency departmentCombined chemo-immunotherapyEnd-of-life chemotherapy useAssociated with healthcare utilizationImmunotherapy useChemo-immunotherapyIncreased healthcare useEnd of lifeAdverse quality of lifeAssociated with higher EDCare unitQuality of lifeSystemic anti-cancer treatmentHospice useDay hospiceHospice enrollmentSEER-Medicare databaseUse of chemotherapyHealthcare useTreatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib
Robinson N, Canavan M, Zhan P, Udelsman B, Pathak R, Boffa D, Goldberg S. Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib. Clinical Lung Cancer 2024 PMID: 39462746, DOI: 10.1016/j.cllc.2024.09.006.Peer-Reviewed Original ResearchNon-small cell lung cancerEGFR-mutant non-small cell lung cancerFirst-line osimertinibContinuation of osimertinibImmune checkpoint inhibitorsTyrosine kinase inhibitorsCell lung cancerRetrospective cohort studyOverall survivalTreatment regimensLung cancerAdvanced epidermal growth factor receptorAssociated with increased PFSAssociated with superior PFSSecond-line treatment regimenEGFR exon 19 deletionRetrospective cohort study of patientsEGFR tyrosine kinase inhibitorsAssociated with prolonged survivalCohort study of patientsSecond-line treatment regimensExon 19 deletionFirst-line therapyEpidermal growth factor receptorFirst-line treatment1378P Improvements in stage IV non-small cell lung cancer survival differ by race in the US
Ayoade O, Canavan M, Kim S, Boffa D. 1378P Improvements in stage IV non-small cell lung cancer survival differ by race in the US. Annals Of Oncology 2024, 35: s865. DOI: 10.1016/j.annonc.2024.08.1433.Peer-Reviewed Original ResearchQuantifying the Association between Pump Use and Breastfeeding Duration
Nardella D, Canavan M, Sharifi M, Taylor S. Quantifying the Association between Pump Use and Breastfeeding Duration. The Journal Of Pediatrics 2024, 274: 114192. PMID: 39004167, PMCID: PMC11499033, DOI: 10.1016/j.jpeds.2024.114192.Peer-Reviewed Original ResearchNon-Hispanic blacksBreastfeeding durationBreastfeeding cessationPump usePregnancy Risk Assessment Monitoring System dataAssociated with longer breastfeeding durationNon-Hispanic whitesMagnitude of associationAssociated with breastfeeding durationLonger breastfeeding durationCox proportional hazards regressionCross-sectional analysisProportional hazards regressionNative American participantsBreastfeeding inequitiesBreastfeeding outcomesInitiate breastfeedingLive-born infantsNon-missing dataUnmarried statusSurvey completionMonitoring system dataLow-incomeStratified analysisHazards regressionPrognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma
Shimer S, Allen O, Yang C, Canavan M, Westvold S, Kim N, Morillo J, Parker T, Wallace N, Smith C, Adelson K. Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma. Journal Of Palliative Medicine 2024, 27: 879-887. PMID: 38990245, DOI: 10.1089/jpm.2023.0530.Peer-Reviewed Original ResearchGoals of carePrognostic awarenessQuality of lifeIllness understandingPrognostic understandingMultiple myelomaHematologic malignanciesAcute leukemiaFaith-based responseInformed treatment choicesChi-square testCohort of patientsLikelihood ratio chi-square testMount Sinai HospitalTreatment goalsMM cohortSinai HospitalCarePatient populationTreatment choiceHospitalized patientsHematologistsAssess discordanceLeukemiaPatientsSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioSurgical and Endoscopic Management of Clinical T1b Esophageal Cancer
Ayoade O, Canavan M, De Santis W, Zhan P, Boffa D. Surgical and Endoscopic Management of Clinical T1b Esophageal Cancer. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 38925509, DOI: 10.1016/j.jtcvs.2024.06.011.Peer-Reviewed Original ResearchEsophageal cancerTumor attributesEsophagectomy patientsEndoscopic treatmentAccelerated time failure modelsEndoscopic managementTumor size > 1 cmFactors associated with upstagingOccult lymph node metastasisAssociated with improved survivalAssociated with lymphovascular invasionEffect of esophagectomyT1b esophageal cancerTreatment naive patientsNational Cancer DatabaseWell-differentiated tumorsKaplan Meier analysisLymph node metastasisPoor tumor differentiationTime failure modelsNodal upstagingLymphovascular invasionOverall survivalEndoscopic patientsMeier analysisSystemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapy
Academic Achievements & Community Involvement
News
News
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- May 17, 2024Source: NewsBreak
Most cancer treatments are useless for patients with advanced tumors near end of life
- May 16, 2024
Oncologists Should Re-Evaluate Cancer Treatments Near End of Life
- March 25, 2024
Contraceptive Access for Adolescents and Young Adults Varies Across Different Demographics